1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
BioInvent International AB

BioInvent International AB

20.68
SEK
+0.33
(+1.60%)
-5.00EPS
1.64BMarket Cap
Oct 29Next Earn
BioInvent International AB
IOB:0H22
(London Stock Exchange (International))

Recent

price

20.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
26.21
37.19
11.5
21.44
10.44
2.74
7.04
3.62
2.79
5.08
5.13
0.36
5.3
1.09
0.68
3.44
3.45
Revenue per Share
-40.61
-20
-50.31
-4.73
-12.01
-15.59
-6.18
-8.08
-8.91
-7.51
-2.66
-5.14
-0.69
-5.02
-6.53
-5.06
-5
Basic EPS, GAAP
-38.69
-18.01
-45.65
-14.35
-17
-12.59
-7.64
-7.42
-10.51
-7
-2.41
-4.78
-0.87
-5.52
-5.93
-3.88
-4.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
23.26
39.32
12.43
11.12
9.52
4.1
18.53
10.47
6.12
8.29
18.88
23.38
24.72
19.9
13.46
8.47
4.82
Book Value per Share
22.3
38.79
12.43
11.12
9.52
4.1
18.53
10.47
6.12
8.29
18.88
23.38
24.72
19.9
13.46
8.47
4.82
Tangible Book Value per Share
3
3
4
4
4
6
10
12
14
18
29
54
62
66
66
66
66
Basic Weighted Avg Shares
83
125
43
82
47
16
71
45
39
94
147
19
326
71
45
226
227
Sales/Revenue/Turnover
-154.27
-57.61
-445.62
-23
-117.02
-600.39
-88.71
-227.38
-319.3
-146.15
-50.86
-1,435.02
-15.48
-518.54
-1,054.58
-155.09
-150.51
Operating Margin (%)
9
6
6
3
2
2
1
3
5
12
12
15
15
9
19
20
19
Depreciation Expense
-128
-67
-188
-18
-54
-91
-63
-101
-123
-139
-76
-278
-43
-330
-429
-333
-329
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-154.95
-53.79
-437.4
-22.08
-115.03
-569.43
-87.8
-223.33
-319.51
-147.89
-51.8
-1,436.46
-13.03
-462.22
-960.87
-146.96
-144.81
Profit Margin (%)
60
125
41
45
46
28
225
111
70
146
720
1,057
997
1,057
848
525
287
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
9
6
22
19
15
8
1
13
LT Debt
74
138
48
49
52
29
230
130
88
169
743
1,367
1,606
1,310
886
558
317
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-197.81
-63.21
-202.45
-37.34
-106.44
-221.49
-48.16
-55.75
-113.07
-107.86
-16.72
-26.39
-2.86
-22.66
-39.11
-46.12
-60.55
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
6
9
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
1,903
1,458
1,637

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
638
506
381
Cash, Cash Equivalents & STI
593
456
341
Accounts Receivable, Net
2
38
30
Inventories
12
11
10
Total Current Liabilities
112
95
94
Payables & Accruals
- -
- -
- -
ST Debt
7
6
9
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
105.18%
2.7%
-37.05%
Free Cash Flow
76.91%
148.85%
-34.7%
Net Income, GAAP
88.45%
172.94%
-22.48%
Sales/Revenue/Turnover
228.37%
357.38%
406.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
5
13
21
45
2025
22
198
- -
3
226
2026
13
13
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.18
-2.09
-1.48
-1.78
-6.53
2025
-1.77
0.59
- -
-1.91
-5.06
2026
-1.81
-1.87
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
BioInvent International AB (publ) is a clinical-stage biotechnology firm dedicated to discovering and advancing innovative immuno-modulatory antibodies to combat cancer. The company leverages its proprietary F.I.R.S.T™ technology platform and n-CoDeR® antibody library to identify novel targets and generate first-in-class drug candidates. Its pipeline includes lead candidates such as BI-1206, an anti-FcγRIIB antibody, currently being evaluated in Phase 2a trials for non-Hodgkin lymphoma in a triple combination with rituximab and Calquence®, and also initiating Phase 2a studies for advanced or metastatic non-small cell lung cancer (NSCLC) and uveal melanoma. Another key asset, BI-1808, an anti-TNFR2 antibody, is progressing through Phase 1/2a studies for solid tumors and cutaneous T-cell lymphoma (CTCL), having recently received Orphan Drug Designation from both the FDA and EMA for T-cell lymphoma and CTCL respectively. While strategically prioritizing its most advanced programs, BioInvent continues to report on other assets. Phase 1 clinical data for BI-1910, a TNFR2 Agonist targeting solid tumors, was presented at SITC 2025. Additionally, BT-001, an oncolytic virus co-developed with Transgene, is being advanced through investigator-led trials for solid tumors. Preclinical and early Phase 1 data for BI-1607, an anti-FcγRIIB antibody, in HER2-positive advanced solid tumors was published, and it is also undergoing a Phase 1b/2a study in combination with other agents for metastatic melanoma. BioInvent generates revenue through research collaborations and licensing agreements with leading pharmaceutical entities, alongside its integrated manufacturing unit that produces antibodies for both internal development and third-party clients across Europe, the United States, Japan, and Australia. The company, established in 1996, operates from its headquarters in Lund, Sweden.

Company News

Company News APIChatGPT

  • accessnewswire.com

    BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025